{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:04:14Z","timestamp":1759341854217},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clinthera.2017.10.019","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T07:17:34Z","timestamp":1511507854000},"page":"2338-2344","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective"],"prefix":"10.1016","volume":"39","author":[{"given":"Vijay N.","family":"Joish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feride","family":"Frech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Lapuerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.10.019_bib1","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1093\/annonc\/mdt377","article-title":"Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n=25 531)","volume":"24","author":"Mocellin","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clinthera.2017.10.019_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00008469-200306000-00004","article-title":"Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases","volume":"12","author":"Crocetti","year":"2003","journal-title":"Eur J Cancer Prev"},{"issue":"4","key":"10.1016\/j.clinthera.2017.10.019_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1016\/j.clinthera.2017.10.019_bib4","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3748\/wjg.v22.i6.2118","article-title":"Healthcare and economic impact of diarrhea in patients with carcinoid syndrome","volume":"22","author":"Broder","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2017.10.019_bib5","unstructured":"Burton T, Lapuerta P. (In process). Economic analysis of inadequate symptom control in carcinoid syndrome. Am J Pharm Benefits. in process."},{"key":"10.1016\/j.clinthera.2017.10.019_bib6","first-page":"1","article-title":"Cost reduction from resolution\/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR","volume":"19","author":"Huynh","year":"2017","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2017.10.019_bib7","year":"2012","journal-title":"Sandostatin LAR\u00ae (octreotide acetate) Prescribing Information"},{"issue":"%","key":"10.1016\/j.clinthera.2017.10.019_bib8","first-page":"161","article-title":"The expanding role of somatostatin analogs in the management of neuroendocrine tumors","volume":"5","author":"Wolin","year":"2012","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.clinthera.2017.10.019_bib9","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: a meta-analysis","volume":"90","author":"Freda","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"28","key":"10.1016\/j.clinthera.2017.10.019_bib10","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Supp 7","key":"10.1016\/j.clinthera.2017.10.019_bib11","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2017.10.019_bib12","year":"2017","journal-title":"Xermelo\u00ae (telotristat ethyl) Prescribing Information"},{"key":"10.1016\/j.clinthera.2017.10.019_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2017.10.019_bib14","unstructured":"National Comprehensive Cancer Network. Guidelines for neuroendocrine tumors v.3.2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site. Accessed August 7, 2017."},{"key":"10.1016\/j.clinthera.2017.10.019_bib15","unstructured":"National Comprehensive Cancer Network. NCCN Drugs & Biologics Compendium. https:\/\/www.nccn.org\/professionals\/drug_compendium\/content\/contents.asp. Accessed August 7, 2017."},{"issue":"18","key":"10.1016\/j.clinthera.2017.10.019_bib16","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 38,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinthera.2017.10.019_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11894-010-0158-4","article-title":"A clinical perspective on gastric neuroendocrine neoplasia","volume":"13","author":"Lawrence","year":"2011","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.clinthera.2017.10.019_bib18","first-page":"89","article-title":"Patients interviewed in TELESTAR, a phase 3 study of telotristat etiprate, report meaningful improvement in carcinoid syndrome","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinol"},{"key":"10.1016\/j.clinthera.2017.10.019_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2009.04083.x","article-title":"Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR","volume":"30","author":"Toumpanakis","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.10.019_bib20","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: A multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2017.10.019_bib21","unstructured":"Optum360\u00ae. EncoderPro.com. https:\/\/www.encoderpro.com\/epro\/. Accessed August 25, 2017."},{"key":"10.1016\/j.clinthera.2017.10.019_bib22","unstructured":"Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017-2019. https:\/\/icer-review.org\/wp-content\/uploads\/2017\/06\/ICER-value-assessment-framework-update-FINAL-062217.pdf. Accessed August 7, 2017."},{"issue":"2","key":"10.1016\/j.clinthera.2017.10.019_bib23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinthera.2017.10.019_bib24","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/MPA.0b013e318279d552","article-title":"Improving the success rate of gluteal intramuscular injections","volume":"42","author":"Boyd","year":"2013","journal-title":"Pancreas"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817310597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817310597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T18:12:23Z","timestamp":1603390343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817310597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0149291817310597"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.10.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}